Evoke Pharma (NASDAQ:EVOK – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, March 13th. Analysts expect the company to announce earnings of ($0.25) per share and revenue of $3.08 million for the quarter.
Evoke Pharma Price Performance
Shares of Evoke Pharma stock opened at $3.78 on Wednesday. The firm has a market cap of $5.62 million, a price-to-earnings ratio of -0.34 and a beta of 0.12. Evoke Pharma has a 52-week low of $3.44 and a 52-week high of $12.32. The stock has a 50-day simple moving average of $4.58 and a 200-day simple moving average of $4.73.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Evoke Pharma in a research note on Tuesday, March 4th. They issued a “sell” rating on the stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- Golden Cross Stocks: Pattern, Examples and Charts
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- How to Capture the Benefits of Dividend Increases
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
